Search





Search





Markets
/
Stocks
/
nasdaq-autl
/

Autolus Therapeutics PLC

AUTL

Add to Watchlist

1.630USD

+0.040+2.52%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

433.83MMarket Cap

LossP/E TTM



Autolus Therapeutics PLC

1.630

+0.040+2.52%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Autolus Therapeutics PLC

Currency: USD Updated: 2026-05-15

Key Insights

Autolus Therapeutics PLC's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 24 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.41.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Autolus Therapeutics PLC's Score

Industry at a Glance

Industry Ranking

24 / 382

Overall Ranking

118 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Autolus Therapeutics PLC Highlights

StrengthsRisks

Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 4339.81% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 75.39M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 75.39M.

Overvalued

The company’s latest PE is -1.50, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 209.95M shares, decreasing 19.28% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 53.15K shares of this stock.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

8.410

Target Price

+428.93%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Autolus Therapeutics PLC is 7.40, ranking 90 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 26.22M, representing a year-over-year increase of 191.89%, while its net profit experienced a year-over-year increase of 2.05%.

Score

Industry at a Glance

Previous score

7.40

Change



Financials

5.14

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.83

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.20

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.42

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.41

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Autolus Therapeutics PLC's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Autolus Therapeutics PLC is 7.88, ranking 73 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.50, which is -25.60% below the recent high of -1.12 and -349.53% above the recent low of -6.75.

Score

Industry at a Glance

Previous score

7.88

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 24/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Autolus Therapeutics PLC is 8.67, ranking 70 out of 382 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 13.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

8.410

Target Price

+428.93%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Autolus Therapeutics PLC

AUTL

Amgen Inc

AMGN

Biogen Inc

BIIB

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

Vertex Pharmaceuticals Inc

VRTX

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Autolus Therapeutics PLC is 8.54, ranking 53 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.79 and the support level at 1.43, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.09

Change

1.45

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.015

Buy

RSI(14)

55.452

Neutral

STOCH(KDJ)(9,3,3)

61.901

Neutral

ATR(14)

0.116

High Vlolatility

CCI(14)

31.795

Neutral

Williams %R

33.333

Buy

TRIX(12,20)

0.431

Sell

StochRSI(14)

25.633

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.622

Buy

MA10

1.620

Buy

MA20

1.554

Buy

MA50

1.488

Buy

MA100

1.539

Buy

MA200

1.565

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Autolus Therapeutics PLC is 7.00, ranking 83 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 78.88%, representing a quarter-over-quarter decrease of 12.89%. The largest institutional shareholder is James Simons, holding a total of 2.30M shares, representing 0.86% of shares outstanding, with 45.16% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Syncona Investment Management Limited

30.73M

MAK Capital One, LLC

30.01M

+15.33%

Clarus Ventures, LLC

20.49M

Blackstone Inc.

20.49M

Armistice Capital LLC

17.50M

+12.18%

Syncona Portfolio Ltd

16.64M

Qatar Investment Authority

15.00M

PPF Group N.V.

14.78M

+1.16%

Polygon Management Ltd.

9.50M

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Autolus Therapeutics PLC is 3.55, ranking 130 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.95. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.